search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


The effect of curcumin and genistein in CF patients with a class III mutation


- candidate number17691
- NTR NumberNTR4585
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR7-mei-2014
- Secondary IDs NL48122.041.14 
- Public TitleThe effect of curcumin and genistein in CF patients with a class III mutation
- Scientific TitleThe effect of curcumin and genistein in CF patients with a class III mutation
- ACRONYMTICTAC
- hypothesisTreatment with a combination of the natural food components curcumin and genistein can lead to a therapeutic level of restoration of the CFTR protein channel activity in patients with a class III, S1251N gating mutation.. Measurements in vitro can predict the individual treatment efficacy of curcumin and genistein.
- Healt Condition(s) or Problem(s) studiedCystic Fibrosis (CF)
- Inclusion criteria• CFTR genotype compound/ S1251N
• Had a rectal biopsy to produce an organoid
• Male and female patients, aged 6 years or older on the date of informed consent or, where appropriate, date of assent
• Signed informed consent form (IC), and where appropriate, signed assent form
- Exclusion criteria• Severe acute exacerbation or pulmonary infection during last four weeks (needing intravenous treatment and/or systemic corticosteroids);
• Use of curcumin and or genistein at start or within four weeks prior to start of the study.
• Participation in another drug-investigating clinical study at the start or within four weeks prior to the start;
• Known cholelithiasis;
• Inability to follow instructions of the investigator.
- mec approval receivedno
- multicenter trialyes
- randomisedno
- group[default]
- TypeSingle arm
- Studytypeintervention
- planned startdate 1-jul-2014
- planned closingdate1-dec-2015
- Target number of participants10
- InterventionsAll patients will use the feeding supplements curcumin and genistein in a dosage that is based on their weight, during the first 8 weeks.
- Primary outcomeSweat chloride concentration (SCC) before and after treatment with curcumin and genistein.
- Secondary outcome• Correlation between individual curcumin+genistein induced CFTR function in vitro (organoid-based measurements) and in vivo treatment effect (lung function, SCC);
• The CFTR stimulating ability of the concentration of curcumin+genistein in the patient’s blood samples, examined by in vitro testing (in the organoid model). We will also determine the plasma levels of curcumin and genistein, only after treatment with curcumin and genistein.
• Pulmonary function (%FEV1) and airway resistance (Rint and bodybox);
• BMI (=weight (in Kg)/Length2 (in cm));
• Quality of life (measured with CFQ-questionnaire);
• Bile salt measurements in plasma and the feces;
• Elastase measurements in the feces.
- TimepointsBefore and after the use of curcumin+genistein
- Trial web site
- statusstopped: trial finished
- CONTACT FOR PUBLIC QUERIES S. Michel
- CONTACT for SCIENTIFIC QUERIES G. Berkers
- Sponsor/Initiator University Medical Center Utrecht (UMCU)
- Funding
(Source(s) of Monetary or Material Support)
ZON-MW, The Netherlands Organization for Health Research and Development
- Publications
- Brief summaryWe hypothesized that treatment with a combination of the natural food components curcumin and genistein can lead to a therapeutic level of restoration of the CFTR protein channel activity in patients with a class III, S1251N gating mutation. Measurements in vitro (in organoids) can predict the individual treatment efficacy of curcumin and genistein. Primary objective is to investigate the therapeutic potential of the natural food components curcumin and genistein in Dutch CF patients carrying the S1251N gating mutation. A secondary objective is to evaluate the correlations between individual curcumin+genistein induced CFTR function in vitro and the in vivo treatment effect. Another secondary objective is to evaluate the CFTR stimulating ability of the concentration of curcumin+genistein in the patient’s blood samples, examined by in vitro testing.Children, adolescents and adults with Cystic Fibrosis who are 6 years or older and have a compound/S1251N class III gating mutation will receive curcumin and genistein in a dosage that is based on their weight during 8 weeks.. Main study parameter will be sweat chloride concentrationbefore and after receiving curcumin+genistein.
- Main changes (audit trail)
- RECORD7-mei-2014 - 22-jun-2016


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl